<DOC>
	<DOC>NCT00298870</DOC>
	<brief_summary>The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the pulmonary tuberculosis with isoniazid.</brief_summary>
	<brief_title>Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Newly diagnosed pulmonary tuberculosis patients Informed consent including pharmacogenomic analysis Abnormal liver and kidney function test before treatment Longterm use of steroids and/or immunodepressants Inadequate clinical conditions</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>isoniazid</keyword>
	<keyword>arylamine N-acetyltransferase 2</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>genetic polymorphisms</keyword>
	<keyword>individualized medicine</keyword>
	<keyword>drug-induced hepatotoxity</keyword>
</DOC>